238 related articles for article (PubMed ID: 35247492)
21. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
[TBL] [Abstract][Full Text] [Related]
22. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis.
Mori S; Kubo S; Akiyoshi T; Yamada S; Miyazaki T; Hotta H; Desaki J; Kishi M; Konishi T; Nishino Y; Miyazawa A; Maruyama N; Shigemoto K
Am J Pathol; 2012 Feb; 180(2):798-810. PubMed ID: 22142810
[TBL] [Abstract][Full Text] [Related]
23. Induction of Anti-agrin Antibodies Causes Myasthenia Gravis in Mice.
Yan M; Liu Z; Fei E; Chen W; Lai X; Luo B; Chen P; Jing H; Pan JX; Rivner MH; Xiong WC; Mei L
Neuroscience; 2018 Mar; 373():113-121. PubMed ID: 29339325
[TBL] [Abstract][Full Text] [Related]
24. Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.
Takata K; Stathopoulos P; Cao M; Mané-Damas M; Fichtner ML; Benotti ES; Jacobson L; Waters P; Irani SR; Martinez-Martinez P; Beeson D; Losen M; Vincent A; Nowak RJ; O'Connor KC
JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217355
[TBL] [Abstract][Full Text] [Related]
25. Autoantibody of NRIP, a novel AChR-interacting protein, plays a detrimental role in myasthenia gravis.
Tsai LK; Chen IH; Chao CC; Hsueh HW; Chen HH; Huang YH; Weng RW; Lai TY; Tsai YC; Tsao YP; Chen SL
J Cachexia Sarcopenia Muscle; 2021 Jun; 12(3):665-676. PubMed ID: 33773096
[TBL] [Abstract][Full Text] [Related]
26. Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models.
Plomp JJ; Morsch M; Phillips WD; Verschuuren JJ
Exp Neurol; 2015 Aug; 270():41-54. PubMed ID: 25620417
[TBL] [Abstract][Full Text] [Related]
27. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
28. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
Baggi F; Antozzi C; Toscani C; Cordiglieri C
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
[TBL] [Abstract][Full Text] [Related]
29. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis.
Aharonov A; Abramsky O; Tarrab-Hazdai R; Fuchs S
Lancet; 1975 Aug; 2(7930):340-2. PubMed ID: 51144
[TBL] [Abstract][Full Text] [Related]
30. [Pathogenic antibodies in myasthenia gravis].
Motomura M
Brain Nerve; 2010 Apr; 62(4):411-8. PubMed ID: 20420182
[TBL] [Abstract][Full Text] [Related]
31. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
Beecher G; Putko BN; Wagner AN; Siddiqi ZA
Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
[TBL] [Abstract][Full Text] [Related]
32. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
Hurst RL; Gooch CL
Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
[TBL] [Abstract][Full Text] [Related]
33. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.
Richman DP; Nishi K; Morell SW; Chang JM; Ferns MJ; Wollmann RL; Maselli RA; Schnier J; Agius MA
Arch Neurol; 2012 Apr; 69(4):453-60. PubMed ID: 22158720
[TBL] [Abstract][Full Text] [Related]
34. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.
Shen C; Lu Y; Zhang B; Figueiredo D; Bean J; Jung J; Wu H; Barik A; Yin DM; Xiong WC; Mei L
J Clin Invest; 2013 Dec; 123(12):5190-202. PubMed ID: 24200689
[TBL] [Abstract][Full Text] [Related]
35. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
[TBL] [Abstract][Full Text] [Related]
36. Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation.
Le Panse R; Berrih-Aknin S
Curr Opin Neurol; 2013 Oct; 26(5):569-76. PubMed ID: 23995274
[TBL] [Abstract][Full Text] [Related]
37. Complement and myasthenia gravis.
Sanderson NSR
Mol Immunol; 2022 Nov; 151():11-18. PubMed ID: 36063582
[TBL] [Abstract][Full Text] [Related]
38. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis.
Huijbers MG; Lipka AF; Plomp JJ; Niks EH; van der Maarel SM; Verschuuren JJ
J Intern Med; 2014 Jan; 275(1):12-26. PubMed ID: 24215230
[TBL] [Abstract][Full Text] [Related]
39. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
[TBL] [Abstract][Full Text] [Related]
40. [Autoantibodies in myasthenia gravis].
Motomura M; Narita Masuda T
Brain Nerve; 2013 Apr; 65(4):433-9. PubMed ID: 23568991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
